[Effect of the recombinant staphylokinase on pancreatic ischemia in severe acute pancreatitis of rats].
OBJECTIVE
To investigate the changes in plasma endothelin-1 (ET-1) , von Willebrand factor (vWF), serum 6-keto-prostaglandin(1alpha) (PGF(1alpha)) , thromboxane B2 (TXB2), platelet aggregation rate maximum (PAGm) and pancreatic blood flow after reproduction of severe acute pancreatitis (SAP) in rat, and the effect of recombinant staphylokinase (r-Sak) on SAP.


METHODS
Eighty-one SD rats were divided randomly into the sham-operated group (n=27), the SAP model group (n=27), and the r-Sak treatment group (n=27). SAP was produced by administration of 5% sodium taurocholate into the pancreatic duct. The abdomen of rats was opened at 6, 12 and 18 hours after reproduction of SAP for determining the pancreatic blood flow. Blood was obtained at 6, 12 and 18 hours after reproduction of SAP for determining the concentration of plasma vWF with enzyme-labeled immunosorbent assay (ELISA). The concentration of plasma ET-1 and serum 6-keto-PGF(1alpha), and TXB2 were detected by radioimmunoassay. The PAGm induced by collagen and eicosanoids was assessed.


RESULTS
Pancreatic blood flow in the SAP group appeared to have a decreasing trend at 6,12 and 18 hours after operation and were significantly decreased at all time points after reproduction of the model, compared with those of the sham-operated group (all P<0.05). The PAGm, content of plasma ET-1, vWF, and TXB2 were significantly increased at all time points after reproduction of the model, while 6-keto-PGF(1alpha) was significantly decreased, compared with those of the sham-operated group (all P < 0.05). Compared with SAP model group, PAGm, the content of plasma ET-1, vWF, and serum TXB2 in the r-Sak group were decreased at all time points, however, the content of serum 6-keto-PGF(1alpha) was increased (all P<0.05).


CONCLUSIONS
The r-Sak can improve pancreatic microcirculation and enhance pancreatic blood flow in rats with SAP, and may be beneficial in the treatment of SAP.
Sha
Jian-ping
JP
Department of Endocrinology, the Southern Medical University, Guangzhou 510515, Guangdong, China. shajianping99@sina.com
Xue
Yao-ming
YM
Chen
Xuan
X
Zhu
Bi-de
BD
Zhang
Xin-sheng
XS
Chen
Wei-yin
WY
Feng
Ben-hua
BH
Zhao
Yan
Y
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000818:Animals; D004195:Disease Models, Animal; D019332:Endothelin-1 / Q000097:blood; D007511:Ischemia / Q000209:etiology / Q000517:prevention & control; D008666:Metalloendopeptidases / Q000494:pharmacology*; D010179:Pancreas / Q000098:blood supply*; D010195:Pancreatitis / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D010974:Platelet Aggregation; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012039:Regional Blood Flow / Q000187:drug effects; D013929:Thromboxane B2 / Q000097:blood; D014841:von Willebrand Factor / Q000378:metabolism
D019332:Endothelin-1; D014841:von Willebrand Factor; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D008666:Metalloendopeptidases; C022653:auR protein, Staphylococcus aureus